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Abstract
Cystic fibrosis (CF) is caused by CFTR (cystic fibrosis transmembrane conductance regulator) gene mutations. We
ascertained five patients with a novel complex CFTR allele, with two mutations, H939R and H949L, inherited in cis in
the same exon of CFTR gene, and one different mutation per patient inherited in trans in a wide population of 289
CaucasianCFsubjectsfromSouthItaly.Thegenotype-phenotyperelationshipinpatientsbearingthiscomplexallele
was investigated. The two associated mutations were related to classical severe CF phenotypes.
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Cystic fibrosis (CF) is the most common lethal auto-
somalrecessivedisorderintheCaucasianpopulationandis
caused by mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene (Ratjen and Döring,
2003; Lommatzsch and Aris, 2009). This disease has a
highly variable clinical presentation with the classical form
of CF involving multiple organs, including recurrent respi-
ratory infections, elevated sweat chloride levels, early-
onset pancreatic insufficiency, and infertility in males;
CFTR-related disorders (CFTR-RD) are estimated to ac-
count for up to 10% of clinical cases, and symptoms may
only affect one organ (Boyle, 2003; Dequeker et al., 2009).
The CF phenotype is highly heterogeneous even between
siblings carrying identical CFTR mutations, suggesting
that the disease severity is affected by the CFTR genotype
as well as by environmental and other genetic factors, such
as alternative genomic loci containing modifier genes
(Rowntree and Harris, 2003). Over 1700 mutations and
polymorphisms have been identified throughout the CFTR
gene (Cystic Fibrosis Mutation Database), and about one-
halfareraremutationsleadingtoanaminoacidsubstitution
into the protein (missense mutations). The number of com-
plex CFTR alleles identified, including double-mutant al-
leles with two mutations inherited in cis in the same allele
has also been growing (Hojo et al., 1998; Abramowicz et
al., 2000; Clain et al., 2001; Rholfs et al., 2002; Niel et al.,
2006;Krasnovetal.,2008,Taulanetal.,2009;Tümmleret
al., 2009; de Prada Merino et al., 2010; Lucarelli et al.,
2010). They are thought to affect the expression of the phe-
notypebymodulatingtheeffectofmutations:thecombina-
tion of two missense mutations on the same allele has been
described clinically either to improve (Dork et al., 1991;
Duarteetal.,1996)orworsen(Hojoetal.,1998)thepheno-
type of CF patients with regard to the most common muta-
tion alone. In some cases the double-mutant allele has been
related with a severe phenotype (Savov et al., 1995; Duarte
et al., 1996), while in other cases complex alleles were not
associatedwithclassicalformofCF(Brugnonetal.,2004).
Thus,furtherdataareneededtoclarifytheirfunctionalrole.
Our Clinic is the referral Center in the Apulia Region of It-
aly for the diagnosis and follow-up of CF with more than
250patientsexaminedyearly(onlysomenewdiagnoses)in
ourInstitute.In2005,wehavedescribedforthefirsttimein
the CF mutation database, the missense mutation H949L, a
nucleotide change of A to T at base pair 2978 in exon 15 of
CFTR gene, resulting in a substitution of histidine residue
to leucine at codon 949, as potentially disease-associated
allele variation. Lately, McGinniss et al. reported that a 12
year-old male patient carrying the same mutation with a
combined dinucleotide TG repeat (of not specified number
ofrepeats)attheintron8–exon9junctionandathymidine
nucleotide tract of 5 nucleotides (5T), had a clinical pheno-
type suggestive of CFTR-RD, with sinus problem, and an
equivocal sweat chloride test result (McGinniss et al.,
2005). Notably, it has been demonstrated that the length of
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Short Communicationthis poly-T at exon 9 splice site of CFTR gene correlated
withthemodulationoftheexon9skippingandwiththefull
length CFTR RNA expression (Chu et al., 1993), and spe-
cifically that the splicing variant 5T allele associated with
partial penetrance of CF disease (Rave-Harel et al., 1997).
The Cystic Fibrosis Mutation Database lists the H939R
missense mutation, a nucleotide substitution of A to G at
base pair 2948 in the same exon of the mutation H949L,
corresponding to a histidine to arginine amino acid change
at codon 939. The Authors also described the clinical
phenothype of the patient, a 17 years old male, with the
F508del/H939R genotype, mild expression of a chronic
lung disease, pancreatic sufficiency, and unequivocally
positive sweat chloride test result.
Inthisstudyweevaluatedthecontributiontothephe-
notype of the two CF-associated allele mutations
[H939R;H949L], combined in cis in the same exon 15 of
CFTR gene, which we observed for the first time in 5 unre-
lated CF patients.
Case histories referring to 289 Caucasian patients
[140 male, 149 female, median age 16 years, (range 1-46)],
who attended since 1996 our CF Center at the Paediatric
Department of the University of Bari, were examined. The
diagnosis of CF was established on the basis of the results
of 2 sweat chloride tests (> 60 mEq/L) by Gibson and
Cooke procedure, and the identification of two CF-disease
causing mutations in trans (Rosenstein and Cutting, 1998;
Kulczycki et al., 2003; De Boeck et al., 2006; Castellani et
al., 2008; Farrel et al., 2008; Dequeker et al., 2009). The
following information was collected: gender, age at diag-
nosis of CF, CFTR genotype, body mass index (BMI), re-
sultsofpulmonaryfunctiontests[medianforcedexpiratory
volume in one second (FEV1), expressed as percentages of
predicted values], and exocrine pancreatic status. We
adopted the Shwachman-Kulczycki score, one of the most
widely used scores, to assess health parameters in our CF
patients (Shwachman and Kulczyzki, 1958). The Brasfield
scoring system based on plain film radiographic findings
was also recorded (Grum and Lynch, 1992). Sputum swabs
were obtained from each patient during routine visits (most
patients were regularly examinated at 4 month intervals) as
wellastwiceduringhospitalization.Chronicairwaysinfec-
tion was defined as the presence of Staphilococcus aureus
and/or Pseudomonas aeruginosa and/or Burkholderia
cepaciainthesputumculturesinthreeconsecutivesamples
collected in a 6-month period (Brett et al., 1992). Informed
consent to collect DNA was obtained from the patients, or,
incaseofminors,fromparentsorguardian.GenomicDNA
wasextractedfromperipheralbloodleukocytesbystandard
inorganic methods, using commercial Kit (Genomic DNA
PurificationKit-FermentasLifeSciences,Canada).AllCF
patients were examined for the most frequent CF mutations
using the RDB (Reverse Dot Blot) commercial kit (Inno-
Lipa CFTR 19, InnoLipa CFTR 17+TnUpdate, InnoLipa
CFTR-Italian regional-Innogenetics, Ghent, Belgium). A
complete scan of the 27 coding/flanking sequences of the
CFTR gene was performed to identify CF alleles carrying
unknown mutations, either by denaturing gradient gel elec-
trophoresis (DGGE), using primers and conditions de-
scribed elsewhere (Fanen et al., 1992; Costes et al., 1993)
or by denaturing high performance liquid chromatography
(DHPLC) (Le Marechall et al., 2001). Abnormal DGGE
and/or DHPLC patterns were followed by automated DNA
sequencing using ABI Prism 3100 (Applied Biosystems,
Warrington, UK). In most cases, the cis versus trans status
of the alterations was obtained by familial segregation as-
sessment, also by using DGGE and automated sequencing
tools. Sputum samples from all patients were mixed with
equal volumes of 1% dithiothreitol (Merck, Darmstadt,
Germany) before incubation at 37 °C for 30 min, and cul-
tured isolates were identified by the Phoenix (Becton
Dickinson, Sparks, MA, USA) automated system (modi-
fied protocol from Efthimiadis et al., 2002).
Detailed information on CFTR genotype, clinical, bi-
ological, and functional data from enrolled CF patients, ex-
cluding those carrying novel complex alleles, will not be
provided because of the different focus of the present re-
port; however this information is available upon request.
During the genetic characterization of the 289 en-
rolled CF patients a new complex allele [H939R;H949L]
(Human Genome Variation Society nomenclature
c:[2816A>G;2846A>T] http://www.hgvs.org/ mutnomen)
was found in five unrelated patients, in whom the two
CF-associated mutations, H939R and H949L, were both
carried in the exon 15 on the same allele, as showed in
Figure 1. The characteristics of these five patients are sum-
marized in Table 1. The segregation analysis showed that
the mother was the carrier of the complex allele
[H939R;H949L] in four cases (patients 2, 3, 4 and 5;
Table 1), while only in one case (patient 1) the father car-
ried this complex allele (Table 1). We did not find patients
bearing the H939R or the H949L mutations alone.
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Figure 1 - Sequence electropherograms showing the complex allele
[H939R;H949L] in CFTR exon 15, (A) forward and (B) reverse (Forward
primer: TCAGTAAGTAACTTTGGCTGC; Reverse primer:
CCTATTGATGGTGGATCAGC). Continuous arrows show the H939R
mutation while the dashed arrows show the H949L mutation.Patient 1 showed CF-related symptoms and signs re-
stricted to one organ. In fact he presented only hepatopathy
with high levels of transaminases combined with elevated
sweat chloride concentration. His Shwachman-Kulczycki
score was excellent; he showed a good nutritional status
and pancreatic sufficiency. The diagnosis of this disease
was made relatively late. The other four patients had signs
and symptoms consistent with classic CF, including
chronic lung and sinus disease, recurrent respiratory infec-
tions, failure to thrive and pancreatic insufficiency. They
all showed abnormal sweat chloride values. Particularly,
patient 3 presented with meconium ileus as a neonate, and
patient 5 showed the most severe pulmonary manifestation
of CF with generalized hyperinflation and diffuse nodular,
cysticandcoarsereticularopacitiesinthelung,withabnor-
mal values on tests of lung function (Table 1).
During our screening analysis we also found thirteen
males affected by congenital bilateral absence of vas
deferens (CBAVD) bearing the intron 8 (IVS-8) variants
TG13-T5 and TG12-T5 in compound heterozygosity with
associated CF-causing mutations, and 2 sisters (of 7 and
9 years old respectively) carrying the [R668C;G576A]
complex allele in compound heterozygosity with F508del
CF mutation, showing a borderline sweat chloride test, re-
current asthmatic bronchitis and pancreatic sufficiency.
Complex disease alleles are rare (we have found only
few cases screening a wide population of CF patients from
SouthItaly)andveryinteresting(thesecondmutationincis
can modulate the effect of the first or viceversa). To our
knowledge the complex allele [H939R;H949L] and its cor-
relationtotheCFphenotypewerenotpreviouslydescribed.
In the afore mentioned database the R248T mutation that
we found in patient 1 was described as “mild”, occurring in
male patients with CBAVD and no other signs or symp-
toms, even when associated with another severe mutation.
The other four patients were compound heterozygotes re-
spectively for G542X, 1259insA, G1349D, F508del and
the two associated mutation in exon 15 [H939R;H949L].
The mutations G542X, 1259insA, G1349D, F508del have
already been described as severe CF-asssociated mutation
(Casalsetal.,1993;Morraletal.,1993;Morraletal.,1994;
Kerem et al., 1995; Estivill et al., 1997; Shrimpton et al.,
1997; Rowntree and Harris 2003; Bompadre et al., 2007;
Castellani et al., 2008). Particularly, 1259insA and
G1349D represent with few other mutations, 4382delA,
I502T, 852del22, 4016insT, D579G, R1158X and L1077P,
almost 20% of the CF alleles found in the Apulian popula-
tion (Castaldo et al., 2005; Polizzi et al., 2005). The
1259insA results in the increase of a string of four As into
five, which leads to the premature termination of product
due to the formation of a stop codon, as described by
Shrimpton et al. (defective protein production, class I mu-
tation) (Shrimpton et al., 1997). Also the G542X prevents
thesynthesisoffull-length,normalCFTRproteinduetothe
creation of a premature termination codon (Rich et al.,
1993; Rowntree and Harris, 2003). On the other hand, the
F508del mutation, a deletion of three bases encoding a
phenylalanineresidueatposition508withinthefirstnucle-
otide binding domain (NBD), affects CFTR maturation
(class II mutations) (Rowntree and Harris, 2003), while the
G1349D plays a role in ATP-dependent opening of the
chloride channel, resulting in a defective CFTR activation
418 Novel complex allele in CF
Table 1 - Clinical features of five unrelated patients with the complex allele [H939R;H949L].
Patients characteris* Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Mutation in trans with [H939R;H949L] R248T G542X 1259insA G1349D F508del
Sex male male male male male
Present age (years) 15 15 17 20 25
Age at diagnosis (years) 14 3 0 10 10
Airways colonization No SA SA SA PA, BC
Age of first colonization (years) / 9 6 12 14
BMI (kg/m
2) 21.9 17.0 15.1 17.6 17.5
FEV1 as % predicted 84.4 114.8 80.9 93.2 53.7
Sweat chloride concentration (mEq/L) 78 100 108 92 95
S-K score 100 70 60 75 40
Brasfield score
 N / A 51 172 1
Pancreas status PS PI PI PI PI
Diagnosis CFTR-RD CF CF CF CF
SA = Staphilococcus aureus,P A=Pseudomonas aeruginosa,B C=Burkholderia cepacia; N/A = not applicable; S-K = Shwachman-Kulczycki: the sys-
tem is based on four parameters (general activity, physical examination, growth and nutrition and chest radiograph x-ray), and is rated as a) excellent:
86-100 b) good: 71-85, c) mild: 56-70, d) moderate: 41-55, and e) severe: < 40 (Shwachman and Kulczyzki, 1958);
scoring system from 3 “mild” to 25
“mostsevere”(Brettetal.,1992)afterx-ray;PS/PI=Pancreaticsufficiency/insufficiency.CF=cysticfibrosis;CFTR-RD=CFtransmembraneconduc-
tance regulator-related disorder.
*Patients’ enrolment was done based on symptoms.andregulation(classIII)(Bompadreetal.,2007).Wespec-
ulate that both mutations H939R and H949L might affect
the second NBD of CFTR and have a role in altering the
conductance of the chloride channel, but to our knowledge
there are no reports on their functions.
In our study, the four patients carrying the complex
allele [H939R;H949L] associated in trans with the severe
mutations G542X, 1259insA, G1349D and F508del pre-
sented the classic CF phenotype. On the contrary, patient 1
who carried the same complex allele with the R248T muta-
tion showed a CFTR-RD (Table 1). This is likely due to the
fact that R248T is a mild mutation (thought to affect CFTR
mRNA splicing based on the database: Cystic Fibrosis Mu-
tation Database), and subjects carrying this mutation might
have a residual function of the CFTR protein. It seems that
the complex allele [H939R;H949L] greatly reduces the re-
sidual function of CFTR and, when also on the other allele
is present a severe mutation which produces a very low re-
sidual function, the combined effect is an overall great re-
duction of CFTR functionality; on the contrary, when the
other allele carries a mild mutation, the overall effect is a
cumulative greater CFTR functionality.
We also found in our CF population subjects carrying
the variant tracts TG13-T5 and TG12-T5, which have been
already described in males with CBAVD in the literature
(Castellani et al., 2008; Dequeker et al., 2009), and the
[R668C;G576A] complex allele. The R668C in exon 13 is
consideredapolymorphism(Pignattietal.,1994)whilethe
G576A, in CFTR exon 12, seems to induce a variable ex-
tent of exon skipping that leads to reduced levels of normal
CFTR transcripts (Pagani et al., 2003).
The complex alleles and their role in disease patho-
genesisstillremainachallengeforbothresearchersandcli-
nicians, thus more information on our newly discovered
complex allele [H939R;H949L] or on the H939R and the
H949L mutations alone would help to study the effect on
the phenotype of these rare mutations.
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